Back to Search
Start Over
Vector-based genetically modified vaccines: Exploiting Jenner's legacy
- Source :
- Vaccine, 34(50), 6436-6448. Elsevier BV, Ramezanpour, B, Haan, I, Osterhaus, A & Claassen, E 2016, ' Vector-based genetically modified vaccines : Exploiting Jenner's legacy ', Vaccine, vol. 34, no. 50, pp. 6436-6448 . https://doi.org/10.1016/j.vaccine.2016.06.059, Vaccine
- Publication Year :
- 2016
-
Abstract
- The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of 'smarter' vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited. In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in order to provide an overview on the use of vector-based technology in the field of GM vaccine development. While still there are only two vector-based vaccines on the human vaccine market, there is ample activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector technology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine development. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of Jenner's vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind.
- Subjects :
- 0301 basic medicine
Genetic Vectors
030106 microbiology
Vaccinia virus
Genetically modified techniques
Article
Adenoviridae
03 medical and health sciences
chemistry.chemical_compound
Preclinical research
SDG 3 - Good Health and Well-being
Immunology and Microbiology(all)
Drug Discovery
Vector-based vaccines
medicine
Journal Article
Humans
Technology, Pharmaceutical
Smallpox
Novel vaccine platforms
Vector (molecular biology)
Molecular Biology
Drug Carriers
Vaccines, Synthetic
General Veterinary
General Immunology and Microbiology
biology
business.industry
Flavivirus
Public Health, Environmental and Occupational Health
Significant part
Viral Vaccines
Vectors
biology.organism_classification
medicine.disease
veterinary(all)
3. Good health
Genetically modified organism
Biotechnology
Infectious Diseases
Genetically modifies vaccines
chemistry
Molecular Medicine
Poxviruses and adenoviruses
Vaccinia
business
Malaria
Subjects
Details
- Language :
- English
- ISSN :
- 0264410X
- Database :
- OpenAIRE
- Journal :
- Vaccine, 34(50), 6436-6448. Elsevier BV, Ramezanpour, B, Haan, I, Osterhaus, A & Claassen, E 2016, ' Vector-based genetically modified vaccines : Exploiting Jenner's legacy ', Vaccine, vol. 34, no. 50, pp. 6436-6448 . https://doi.org/10.1016/j.vaccine.2016.06.059, Vaccine
- Accession number :
- edsair.doi.dedup.....899d07357db9b6fe15fa18b642f6ce78